Page last updated: 2024-08-24

valsartan and Lymphoma, Non-Hodgkin

valsartan has been researched along with Lymphoma, Non-Hodgkin in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hino, M; Nakamae, H; Nakamae, M; Nakane, T; Ohta, K; Terada, Y; Tsumura, K; Yamane, T1

Trials

1 trial(s) available for valsartan and Lymphoma, Non-Hodgkin

ArticleYear
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
    Cancer, 2005, Dec-01, Volume: 104, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Cyclophosphamide; Doxorubicin; Female; Hemodynamics; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Prednisone; Tetrazoles; Valine; Valsartan; Vincristine

2005